eCQM QICore Content Implementation Guide
2025.0.0 - CI Build
eCQM QICore Content Implementation Guide, published by cqframework. This guide is not an authorized publication; it is the continuous build for version 2025.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/ecqm-content-qicore-2025/ and changes regularly. See the Directory of published versions
This page provides a list of the FHIR artifacts defined as part of this implementation guide.
These define measures as part of content in this implementation guide.
Anticoagulation Therapy for Atrial Fibrillation/FlutterFHIR |
Ischemic stroke patients with atrial fibrillation/flutter who are prescribed or continuing to take anticoagulation therapy at hospital discharge |
Antidepressant Medication ManagementFHIR |
Percentage of patients 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment. Two rates are reported. a. Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks). b. Percentage of patients who remained on an antidepressant medication for at least 180 days (6 months). |
Antithrombotic Therapy By End of Hospital Day 2FHIR |
Ischemic stroke patients administered antithrombotic therapy by the end of hospital day 2 |
Appropriate Testing for PharyngitisFHIR |
The percentage of episodes for patients 3 years and older with a diagnosis of pharyngitis that resulted in an antibiotic order on or three days after the episode date and a group A streptococcus (strep) test in the seven-day period from three days prior to the episode date through three days after the episode date |
Appropriate Treatment for ST-Segment Elevation Myocardial Infarction (STEMI) Patients in the Emergency Department FHIR |
Percentage of emergency department (ED) encounters for patients 18 years and older with a diagnosis of ST-segment elevation myocardial infarction (STEMI) that received appropriate treatment, defined as fibrinolytic therapy within 30 minutes of ED arrival, percutaneous coronary intervention (PCI) within 90 minutes of ED arrival, or discharge to an acute care facility within 45 minutes of ED arrival |
Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation TherapyFHIR |
Percentage of patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT. |
Breast Cancer ScreeningFHIR |
Percentage of women 40-74 years of age who had a mammogram to screen for breast cancer in the 27 months prior to the end of the Measurement Period |
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract SurgeryFHIR |
Percentage of cataract surgeries for patients aged 18 and older with a diagnosis of uncomplicated cataract and no significant ocular conditions impacting the visual outcome of surgery and had best-corrected visual acuity of 20/40 or better (distance or near) achieved in the operative eye within 90 days following the cataract surgery |
Cervical Cancer ScreeningFHIR |
Percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria: - Women age 21-64 who had cervical cytology performed within the last 3 years - Women age 30-64 who had cervical human papillomavirus (HPV) testing performed within the last 5 years |
Cesarean BirthFHIR |
Nulliparous patients with a term, singleton baby in a vertex position delivered by cesarean birth |
Childhood Immunization StatusFHIR |
Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three or four H influenza type B (HiB); three hepatitis B (HepB); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday |
Children Who Have Dental Decay or CavitiesFHIR |
Percentage of children, 1-20 years of age at the start of the measurement period, who have had dental decay or cavities during the measurement period as determined by a dentist |
Closing the Referral Loop: Receipt of Specialist ReportFHIR |
Percentage of patients with referrals, regardless of age, for which the referring clinician receives a report from the clinician to whom the patient was referred |
Colorectal Cancer ScreeningFHIR |
Percentage of adults 45-75 years of age who had appropriate screening for colorectal cancer |
Controlling High Blood PressureFHIR |
Percentage of patients 18-85 years of age who had a diagnosis of essential hypertension starting before and continuing into, or starting during the first six months of the measurement period, and whose most recent blood pressure was adequately controlled (<140/90 mmHg) during the measurement period |
Core Clinical Data Elements HW Mortality FHIR |
This logic is intended to extract electronic clinical data. This is not an electronic clinical quality measure and this logic will not produce measure results. Instead, it will produce a file containing the data that CMS will link with administrative claims to risk adjust the Hybrid HWM outcome measure. It is designed to extract the first resulted set of vital signs and basic laboratory results obtained from hospitalizations for adult Medicare Fee-For-Service (FFS) and Medicare Advantage (MA) patients admitted to acute care hospitals. |
Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF less than or equal to 40%)FHIR |
Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior MI or a current or prior left ventricular ejection fraction (LVEF) <=40% who were prescribed beta-blocker therapy |
Dementia: Cognitive AssessmentFHIR |
Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within the 12 months preceding a dementia encounter during the measurement period. |
Depression Remission at Twelve MonthsFHIR |
The percentage of adolescent patients 12 to 17 years of age and adult patients 18 years of age or older with major depression or dysthymia who reached remission 12 months (+/- 60 days) after an index event |
Diabetes: Glycemic Status Assessment Greater Than 9%FHIR |
Percentage of patients 18-75 years of age with diabetes who had a glycemic status assessment (hemoglobin A1c [HbA1c] or glucose management indicator [GMI]) > 9.0% during the measurement period |
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes CareFHIR |
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once during the measurement period. |
Discharged on Antithrombotic TherapyFHIR |
Ischemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge |
Documentation of Current Medications in the Medical RecordFHIR |
Percentage of visits for patients aged 18 years and older for which the eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter |
Emergency Care Access & Timeliness (HOQR)FHIR |
This measure assesses the variation in access and timeliness of emergency care to support hospital quality improvement for patients requiring emergency care in an emergency department (ED). This measure is designed to align with incentives to promote improved care both in EDs and the broader health system to help identify where patients do not receive timely access to emergency care. Emergency care access and timeliness gaps are inclusive of several concepts pertaining to boarding and crowding in an ED, including significantly longer ED wait times, higher left without being seen rates, longer boarding times, and longer total length of stay in the ED. |
Emergency Care Access & Timeliness (REHQR)FHIR |
This measure assesses the variation in access and timeliness of emergency care to support rural emergency hospital (REH) quality improvement for patients requiring emergency care in an emergency department (ED). This measure is designed to align with incentives to promote improved care both in EDs and the broader health system to help identify where patients do not receive timely access to emergency care. Emergency care access and timeliness gaps are inclusive of several concepts pertaining to boarding and crowding in an ED, including significantly longer ED wait times, higher left without being seen rates, longer boarding times, and longer total length of stay in the ED. |
Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography in Adults - Clinician FHIR |
This measure provides a standardized method for monitoring the performance of diagnostic CT to discourage unnecessarily high radiation doses, a risk factor for cancer, while preserving image quality. It is expressed as a % of patients with CT exams that are out-of-range based on having either excessive radiation dose or inadequate image quality relative to evidence-based thresholds based on the clinical indication for the exam. All diagnostic CT exams of specified anatomic sites performed in inpatient, outpatient and ambulatory care settings are eligible. This measure is not telehealth eligible. This eCQM requires the use of additional software to access primary data elements stored within radiology electronic health records and translate them into data elements that can be ingested by this eCQM. Additional details are included in the Guidance field. |
Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography in Adults - Facility IQR FHIR |
This measure provides a standardized method for monitoring the performance of diagnostic CT to discourage unnecessarily high radiation doses, a risk factor for cancer, while preserving image quality. This measure is expressed as a percentage of CT exams that are out-of-range based on having either excessive radiation dose or inadequate image quality relative to evidence-based thresholds based on the clinical indication for the exam. All diagnostic CT exams of specified anatomic sites performed in hospital inpatient care settings are eligible. This eCQM requires the use of additional software to access primary data elements stored within radiology electronic health records and translate them into data elements that can be ingested by this eCQM. Additional details are included in the Guidance field. |
Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography in Adults - Facility OQR FHIR |
This measure is an episode of care measure that provides a standardized method for monitoring the performance of diagnostic CT to discourage unnecessarily high radiation doses, a risk factor for cancer, while preserving image quality. This measure is expressed as a percentage of CT exams that are out-of-range based on having either excessive radiation dose or inadequate image quality relative to evidence-based thresholds based on the clinical indication for the exam. All diagnostic CT exams of specified anatomic sites performed in hospital non-inpatient care settings (including emergency settings) are eligible. This eCQM requires the use of additional software to access primary data elements stored within radiology electronic health records and translate them into data elements that can be ingested by this eCQM. Additional details are included in the Guidance field. |
Functional Status Assessment for Total Hip ReplacementFHIR |
Percentage of patients 19 years of age and older who received an elective primary total hip arthroplasty (THA) and completed a functional status assessment within 90 days prior to the surgery and in the 300 - 425 days after the surgery |
HIV ScreeningFHIR |
Percentage of patients aged 15-65 at the start of the measurement period who were between 15-65 years old when tested for human immunodeficiency virus (HIV). |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)FHIR |
Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) <=40% who were prescribed or already taking ACE inhibitor or ARB or ARNI therapy during the measurement period |
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)FHIR |
Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) <= 40% who were prescribed or already taking beta-blocker therapy during the measurement period |
Hospital Harm - Acute Kidney InjuryFHIR |
The measure assesses the number of inpatient hospitalizations for patients age 18 and older who have an acute kidney injury (stage 2 or greater) that occurred during the encounter. Acute kidney injury (AKI) stage 2 or greater is defined as a substantial increase in serum creatinine value, or by the initiation of kidney dialysis (continuous renal replacement therapy (CRRT), hemodialysis or peritoneal dialysis). |
Hospital Harm - Opioid-Related Adverse EventsFHIR |
This measure assesses the number of inpatient hospitalizations for patients age 18 and older who have been administered an opioid medication and are subsequently administered an opioid antagonist within 12 hours, an indication of an opioid-related adverse event |
Hospital Harm - Postoperative Respiratory FailureFHIR |
This measure assesses the number of elective inpatient hospitalizations for patients aged 18 years and older without an obstetrical condition who have a procedure resulting in postoperative respiratory failure (PRF) |
Hospital Harm - Pressure InjuryFHIR |
The measure assesses the number of inpatient hospitalizations for patients aged 18 and older who suffer the harm of developing a new stage 2, stage 3. stage 4. deep tissue, or unstageable pressure injury |
Hospital Harm - Severe HyperglycemiaFHIR |
This measure assesses the number of inpatient hospital days for patients age 18 and older with a hyperglycemic event (harm) per the total qualifying inpatient hospital days for that encounter |
Hospital Harm - Severe HypoglycemiaFHIR |
The measure assesses the number of inpatient hospitalizations for patients age 18 and older who were administered at least one hypoglycemic medication during the encounter, who suffer the harm of a severe hypoglycemic event during the encounter |
Hospital Harm – Falls with InjuryFHIR |
This ratio measure assesses the number of inpatient hospitalizations where at least one fall with a major or moderate injury occurs among the total qualifying inpatient hospital days for patients aged 18 years and older |
Intensive Care Unit Venous Thromboembolism ProphylaxisFHIR |
This measure assesses the number of patients who received Venous Thromboembolism (VTE) prophylaxis on the day of or the day after the initial admission (or transfer) to the Intensive Care Unit (ICU) or on the day of or the day after surgery end date for surgeries that end the day after ICU admission (or transfer) or have documentation why no VTE prophylaxis was given between the day of arrival and the day after ICU admission (for patients directly admitted as inpatients to the ICU) or on the day of or the day after surgery end date for surgeries that end the day after ICU admission (or transfer) |
Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder CancerFHIR |
Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging |
Malnutrition Care ScoreFHIR |
This measure assesses the percentage of eligible encounters of adults aged 18 years and older at the start of the eligible encounter during the measurement period, with a length of stay equal to or greater than 24 hours, who received optimal malnutrition care where care performed was appropriate to the patient’s level of malnutrition risk and severity. Malnutrition care best practices recommend that for each eligible encounter, adult inpatients are (1) screened for malnutrition risk or for a dietitian referral order to be placed, (2) assessed by a registered dietitian (RD) or registered dietitian nutritionist (RDN) to confirm findings of malnutrition risk, and if identified with a “moderate” or “severe” malnutrition status in the current performed nutrition assessment, (3) receive a “moderate” or “severe” malnutrition diagnosis by a physician or eligible clinician as defined by the Centers for Medicare & Medicaid Services (CMS), and (4) have a current nutrition care plan performed by an RD/RDN. |
Oncology: Medical and Radiation Pain Intensity QuantifiedFHIR |
Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up PlanFHIR |
Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the measurement period AND who had a follow-up plan documented if BMI was outside of normal parameters |
Preventive Care and Screening: Screening for Depression and Follow-Up PlanFHIR |
Percentage of patients aged 12 years and older screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of or up to two days after the date of the qualifying encounter |
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up DocumentedFHIR |
Percentage of patient visits for patients aged 18 years and older seen during the measurement period who were screened for high blood pressure AND a recommended follow-up plan is documented, as indicated, if blood pressure is elevated or hypertensive |
Primary Caries Prevention Intervention as Offered by DentistsFHIR |
Percentage of children, 1-20 years of age, who received two fluoride varnish applications during the measurement period as determined by a dentist |
Primary Open-Angle Glaucoma (POAG): Optic Nerve EvaluationFHIR |
Percentage of patients aged 18 years and older with a diagnosis of primary open-angle glaucoma (POAG) who have an optic nerve head evaluation during one or more visits within during the measurement period |
Safe Use of Opioids - Concurrent PrescribingFHIR |
Proportion of inpatient hospitalizations for patients 18 years of age and older prescribed, or continued on, two or more opioids or an opioid and benzodiazepine concurrently at discharge |
Severe Obstetric ComplicationsFHIR |
Patients with severe obstetric complications that occur during the inpatient delivery hospitalization |
Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic HyperplasiaFHIR |
Percentage of patients with an office visit within the measurement period and with a new diagnosis of clinically significant Benign Prostatic Hyperplasia who have International Prostate Symptoms Score (IPSS) or American Urological Association (AUA) Symptom Index (SI) documented at time of diagnosis and again 6-12 months later with an improvement of 3 points |
Venous Thromboembolism ProphylaxisFHIR |
This measure assesses the number of patients who received Venous Thromboembolism (VTE) prophylaxis or have documentation why no VTE prophylaxis was given between the day of arrival to the day after hospital admission or surgery end date for surgeries that end the day after hospital admission |
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/AdolescentsFHIR |
Percentage of patients 3-17 years of age who had an outpatient visit with a primary care physician (PCP) or obstetrician/gynecologist (OB/GYN) and who had evidence of the following during the measurement period.
|
These define logic, asset collections and other libraries as part of content in this implementation guide.
AHAOverall |
This version of the AHAOverall library is patterned after HFCommonDefinitionsQDM library version ‘3.0.000’ |
AdultOutpatientEncounters |
This library contains a definition used to identify denominator qualifying encounters. |
AdvancedIllnessandFrailty |
This library contains definitions used to exclude patients 66 and older with an indication of frailty who also meet advanced illness criteria, and patients 66 and older who are living long term in a nursing home. |
AlaraCommonFunctions |
Provides common functions used in the Alara CT measures for determining qualifying scans and extracting noise and dose values. |
Antibiotic |
This library contains functions used to exclude patients with a history of comorbid conditions, competing diagnoses, or antibiotic medications. |
CMS0334FHIRPCCesareanBirth |
CMS0334FHIRPCCesareanBirth |
CMS1017FHIRHHFI |
CMS1017FHIRHHFI |
CMS1028FHIRPCSevereOBComps |
CMS1028FHIRPCSevereOBComps |
CMS104FHIRSTKDCAntithrombotic |
CMS104FHIRSTKDCAntithrombotic |
CMS1056CTClinicalFHIR |
CMS1056CTClinicalFHIR |
CMS1074FHIRCTIQR |
CMS1074FHIRCTIQR |
CMS108FHIRVTEProphylaxis |
CMS108FHIRVTEProphylaxis |
CMS117FHIRChildhoodImmunizationStatus |
CMS117FHIRChildhoodImmunizationStatus |
CMS1206FHIRCTOQR |
CMS1206FHIRCTOQR |
CMS1218FHIRHHRF |
CMS1218FHIRHHRF |
CMS122FHIRDiabetesAssessGreaterThan9Percent |
CMS122FHIRDiabetesAssessGreaterThan9Percent |
CMS1244FHIRECATHOQR |
CMS1244FHIRECATHOQR |
CMS124FHIRCervicalCancerScreening |
CMS124FHIRCervicalCancerScreening |
CMS125FHIRBreastCancerScreening |
CMS125FHIRBreastCancerScreening |
CMS1264FHIRECATREHQR |
CMS1264FHIRECATREHQR |
CMS128FHIRAntidepressantMedManagement |
CMS128FHIRAntidepressantMedManagement |
CMS130FHIRColorectalCancerScreening |
CMS130FHIRColorectalCancerScreening |
CMS133FHIRCataracts2040BCVAwithin90Days |
CMS133FHIRCataracts2040BCVAwithin90Days |
CMS135FHIRHFACEIorARBorARNIforLVSD |
CMS135FHIRHFACEIorARBorARNIforLVSD |
CMS142FHIRDRCommunicationWithPhysicianManagingDiabetes |
CMS142FHIRDRCommunicationWithPhysicianManagingDiabetes |
CMS143FHIRPOAGOpticNerveEvaluation |
CMS143FHIRPOAGOpticNerveEvaluation |
CMS144FHIRHFBetaBlockerTherapyforLVSD |
CMS144FHIRHFBetaBlockerTherapyforLVSD |
CMS145FHIRCADBetaBlockerTherapyPriorMIorLVSD |
CMS145FHIRCADBetaBlockerTherapyPriorMIorLVSD |
CMS146FHIRAppropriateTestingforPharyngitis |
CMS146FHIRAppropriateTestingforPharyngitis |
CMS149FHIRDementiaCognitiveAssessment |
CMS149FHIRDementiaCognitiveAssessment |
CMS155FHIRWeightAssessandCounselforKids |
CMS155FHIRWeightAssessandCounselforKids |
CMS159FHIRDepressionRemissionatTwelveMonths |
CMS159FHIRDepressionRemissionatTwelveMonths |
CMS165FHIRControllingHighBloodPressure |
CMS165FHIRControllingHighBloodPressure |
CMS190VTEProphylaxisICUFHIR |
CMS190VTEProphylaxisICUFHIR |
CMS22FHIRPCSBPScreeningFollowUp |
CMS22FHIRPCSBPScreeningFollowUp |
CMS2FHIRPCSDepressionScreenAndFollowUp |
CMS2FHIRPCSDepressionScreenAndFollowUp |
CMS349FHIRHIVScreening |
CMS349FHIRHIVScreening |
CMS506FHIRSafeUseofOpioids |
CMS506FHIRSafeUseofOpioids |
CMS50FHIRCRLReceiptofSpecialistReport |
CMS50FHIRCRLReceiptofSpecialistReport |
CMS56FHIRFunctionalStatusAssessmentforTotalHipReplacement |
CMS56FHIRFunctionalStatusAssessmentforTotalHipReplacement |
CMS645FHIRBoneDensityProstateCancerAndrogenDeprivationTherapy |
CMS645FHIRBoneDensityProstateCancerAndrogenDeprivationTherapy |
CMS646FHIRIntravesicalBacillusCalmetteGuerinForBladderCancer |
CMS646FHIRIntravesicalBacillusCalmetteGuerinForBladderCancer |
CMS68FHIRDocumentationofCurrentMedications |
CMS68FHIRDocumentationofCurrentMedications |
CMS69FHIRPCSBMIScreenAndFollowUp |
CMS69FHIRPCSBMIScreenAndFollowUp |
CMS71FHIRSTKAnticoagAFFlutter |
CMS71FHIRSTKAnticoagAFFlutter |
CMS72FHIRSTKAntithromboticDay2 |
CMS72FHIRSTKAntithromboticDay2 |
CMS74FHIRPrimaryCariesPreventionasOfferedbyDentists |
CMS74FHIRPrimaryCariesPreventionasOfferedbyDentists |
CMS75FHIRChildrenWhoHaveDentalDecayOrCavities |
CMS75FHIRChildrenWhoHaveDentalDecayOrCavities |
CMS771FHIRUrinarySymptomScoreChangeBenignProstaticHyperplasia |
CMS771FHIRUrinarySymptomScoreChangeBenignProstaticHyperplasia |
CMS816FHIRHHHypo |
CMS816FHIRHHHypo |
CMS819FHIRHHORAE |
CMS819FHIRHHORAE |
CMS826FHIRHHPI |
CMS826FHIRHHPI |
CMS832HHAKIFHIR |
CMS832HHAKIFHIR |
CMS871HHHyperFHIR |
CMS871HHHyperFHIR |
CMS986FHIRMalnutritionScore |
CMS986FHIRMalnutritionScore |
CMS996FHIRAptTxforSTEMI |
CMS996FHIRAptTxforSTEMI |
CMSFHIR844HybridHospitalWideMortality |
CMSFHIR844HybridHospitalWideMortality |
CQMCommon |
This library contains declarations that are commonly used in eCQMs and shared across the logic of multiple measures, such as the Encounter Inpatient value set, and the Inpatient Encounter population criteria definition. This library also contains functions for calculating hospitalization duration as well as hospital arrival and departure times. |
CumulativeMedicationDuration |
This library provides cumulative medication duration calculation logic for use with FHIR medication prescription, administration, and dispensing resources. The logic here follows the guidance provided as part of the 5.6 version of Quality Data Model. |
FHIRHelpers |
This library defines functions to convert between FHIR data types and CQL system-defined types, as well as functions to support FHIRPath implementation. For more information, the FHIRHelpers wiki page: https://github.com/cqframework/clinical_quality_language/wiki/FHIRHelpers |
Hospice |
This library contains a definition used to exclude patients who are in hospice care for any part of the measurement period. |
HospitalHarm |
Utility functions designed for use specifically, but not exclusively, in Hospital Harm, Patient Safety measures. Using QI-Core 6.0.0+, this library uses the Claim resource to fetch Present On Admission and Principal Diagnosis |
OncologyPainIntensityQuantifiedFHIR |
OncologyPainIntensityQuantifiedFHIR |
PCMaternal |
This library specifies common data elements used by PC01, PC02, PC07. |
PalliativeCare |
This library contains a definition used to exclude patients receiving palliative care for any part of the measurement period. |
QICoreCommon |
Common terminologies and functions used in QI-Core-based CQL artifacts |
Status |
This library contains functions used to constrain FHIR resource elements for measures authored by NCQA, based on QICore 6.0.0 resources including IG and authoring patterns. The functions may appear similar to some QICoreCommon functions but differ in that they have constraints that are relevant for measures authored by NCQA. |
SupplementalDataElements |
This is the QI-Core 6.0.0 version of the Supplemental Data Elements library containing the CMS SDE definitions for Payer, Race, Ethnicity and Sex |
TJCOverall |
Common functions and definitions used by TJC measures |
VTE |
Definitions and functions used for VTE measures, including VTE Initial Population. |
eCQM Update QI Core 2025 |
This library is an example final draft of a version manifest (also referred to as an expansion profile) that specifies expansion rules for a set of value sets used for an example set of EP/EC measures. |
eCQM Update QI Core 2025 |
This library is an example of a release version manifest (also referred to as an expansion profile) that specifies expansion rules for a set of value sets used for an example set of EP/EC measures. |
eCQM Update QI Core 2025 |
This library is an example final draft of a version manifest (also referred to as an expansion profile) that specifies expansion rules for a set of value sets used for an example set of EP/EC measures. |
eCQM Update QI Core 2025 |
This library is an example final draft of a version manifest (also referred to as an expansion profile) that specifies expansion rules for a set of value sets used for an example set of EP/EC measures. |